Adenovirus vaccines of types 3, 4, and 7 originally produced 90% serological conversion in man (3) and reduced hospital admissions for adenovirus disease by 90 to 98%. Sherwood et al. (9) , however, later reported that a commercial vaccine of adenovirus types 4 and 7 reduced hospital admissions of vaccinated army recruits by only 50%. They ascribed their results to differences in antigenic mass.
Aside from Sherwood's report, the potency of commercial adenovirus vaccines generally has been known to be a problem, and it appeared that an experimental effort to obtain higher and more consistent antigenic yields would be worthwhile. Since the problenis of itaining increased growth of the viruses in tissue culture had been extensively investigated in the past, the most promising approach appeared to be concentration of the virus before inactivation. Additionally, since recent reports (4, 12) Fractionation by calcium phosphate (CaHPO4). The brushite form of CaHPO4 was prepared by the method of Tiselius et al. (11) . Equal volumes of 0.5 M CaCl2 and 0.5 M Na2HPO4 were run from two separatory funnels (120 drops per min) into a beaker containing a Teflon-coated magnetic bar and were mounted over a magnetic stirrer. The precipitate was allowed to settle, the supernatant fluid was decanted, and the precipitate was washed four times with equal volumes of distilled water. The precipitate was then resuspended to the original volume with 0.001 M phosphate buffer (pH 7.2) and was sterilized by autoclaving.
A 50 X concentrate of the L3G strain of ADV-3 was then prepared by the methanol procedure, and 20 ml was mixed with a 97-ml suspension of calcium phosphate. Virus was allowed to adsorb for 2 hr at room temperature, centrifuged at 1,000 rev/min, and the supernatant fluid was decanted and saved for later assay. By use of a modification of Simon's procedure (10), the sediment was successively extracted with 25-ml portions of phosphate buffer (pH 7. Assay procedures. The methods employed for the measurement of infectivity (TCID5o), complement fixation (CF), and hemagglutination (HA) have been described (2) . Protein nitrogen was determined by Kjeldahl digestion, followed by color development with Nessler's reagent (6) . Total nitrogen (N) was determined on untreated material and nonprotein nittogen (NPN) on supernatant fluids after precipitation of the protein. The protein nitrogen was the difference between total N and NPN. ADV vaccines were assayed for potency in 350 to 400-g guinea pigs simultaneously with an NIH reference vaccine (8A) as a positive control. The animals were bled by cardiac puncture and given a single 5-ml intraperitoneal injection of fivefold diluted vaccine. Twenty-eight days after vaccination, all animals were bled again. The antibody content of the pre-and postvaccination sera was determined by three serum neutralization methods: (i) the presence of antibody in each serum diluted 1:4 was determined, and the 50% protective vaccine dose (PD5o) in animals was calculated by the method of Reed and Muench (8); (ii) samples of serum from each animal in the group receiving a given vaccine dilution were pooled and titrated for antibody content, and (iii) individual sera were titrated for antibody content and geometric mean titers were calculated. In each serum neutralization test, equal amounts of serum and homologous virus (10 to 30 TCID5o) were mixed and incubated at 37 C for 2 hr. Each oftwo to four AGMK cultures was inoculated with 0.2 ml of the niixture and was incubated at 37 C with daily examinations for cytopathology. Tests were terminated when the virus control cultures showed 3 to 4 plus cytopathology.
RESULTS
Concentration and purification by methanol. Pools (1 to 3 liters) of ADV 1, 2, 3, 5, or 7 were concentrated (20 or 50 X) by methanol. The methanol-containing supernatant fluids, the virus concentrates, and samples from the original untreated preparations were assayed for protein nitrogen, HA, CF, and TCID50. Methanol treatment results in a 8-to 32-fold increase in HA and CF titers, and a 20-to 178-fold increase in TCID50 ( Table 1 ). The concentrates, however, contained only 5 to 20% of the protein nitrogen found in the untreated preparations. Results obtained by similar assay of the supernatant fluids confirmed the observation that only a fraction of the total' virus in the crude harvests was not removed by methanol treatment.
Because the major fraction of the viral antigens was recovered in the concentrates, it was reasonable to assume that the protein eliminated from the concentrates was of host-cell origin. To confirm the assumption and to determine the extent of residual host antigens in the concentrates, the concentrates were assayed in a complement-fixation test which contained goat serum hyperimmune to normal monkey serum (Hyland Laboratories, Los Angeles, Calif.); the The infectivity of the preparations could not be measured after 3 days of inactivation (Fig. 1) . Figure 2 demonstrates a 16-fold reduction of HA in the preparations between 8 and 10 days of inactivation. Unconcentrated and 20 X methanol-concentrated preparations of types 1, 2, 5, and 7 ADV were also inactivated by formaldehyde, a-s described. Inactivation rates similar to that obtained with the type 3 virus were observed (Fig.   3) .
Potency in animals. From a 10-liter pool of ADV type 3 (L3G), the following formaldehydekilled vaccines were prepared and potency was tested as described above: unconcentrated, a 20 x methanol concentrate, and a soluble antigens pool. The unconcentrated vaccine failed to pass the minimal required potency when compared with the NIH reference vaccine, whereas the 20 X methanol concentrate was definitely of in either the crude or concentrated preparations beyond 3 days of inactivation. Since 15 days were used for the total inactivation time for these preparations, the procedure offers a considerable safety margin. Extraction of the soluble antigens from an adenovirus preparation also produced a potent vaccine. This observation confirms the findings of Wilcox and Ginsberg (12) and Kasel et al. (4) , who reported that both type-specific and group-specific complement-fixing antigens induced the formation of type-specific neutralizing antibody.
The data further indicate that methanol concentration, as well as the extraction of soluble antigens by calcium phosphate fractionation, results in virus preparations that contain minimal amounts of host protein.
Although the type 3 adenovirus preparation (L3G) used in these experiments was found to be free of the SV40 virion, "hybridization" with the simian virus genome was demonstrated at a later date. Thus, the information derived from the studies with this virus strain may or may not be applicable to "unhybridized" virus, which should be used for human vaccine production.
